Evaluation of a clinical service to support the uptake of breast cancer prevention medications by women at increased risk of the disease
- Conditions
- Prevention of breast cancer in clients at increased riskCancer
- Registration Number
- ISRCTN15718519
- Lead Sponsor
- Peter MacCallum Cancer Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- Female
- Target Recruitment
- 250
Eligibility Criteria for clients:
1. Female.
2. Age between 20 and 70 years old
3. Residual lifetime breast cancer risk of at least 20% or a 10-year risk of at least 5%, or history of lobular carcinoma in situ (LCIS) or atypical hyperplasia, or previous thoracic irradiation
4. Does not require germline genetic testing to further clarify the risk
5. Does not carry a pathogenic variant in a high-risk breast cancer predisposition gene and is not an untested 1st-degree relative for carriers
6. No history of invasive breast cancer or ductal carcinoma in situ (DCIS)
7. No history of bilateral mastectomy
8. No prior or current use of breast cancer prevention medications
Eligibility for clinicians:
Clinicians working in clinics from which eligible clients could be referred
Not meeting the inclusion criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method se of risk-reducing medications measured using data documented in the medical records or self-reported at 12 months after a Risk Management Consultation
- Secondary Outcome Measures
Name Time Method